FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309494706> ?p ?o ?g. }

• W4309494706 endingPage "2280" @default.
• W4309494706 startingPage "2270" @default.
• W4309494706 abstract "Potent P2Y12 agents such as ticagrelor and prasugrel are increasingly utilized across the clinical spectrum of patients undergoing percutaneous coronary intervention (PCI). There is a paucity of data supporting their use in a patient population inclusive of both acute coronary syndrome (ACS) and chronic coronary syndrome (CCS) patients.The authors compared the efficacy and safety of ticagrelor and prasugrel in a real-world contemporary PCI cohort.Consecutive patients undergoing PCI between 2014 and 2019 discharged on either prasugrel or ticagrelor were included from the prospectively collected institutional PCI registry. Primary endpoint was the composite of death and myocardial infarction (MI), with secondary outcomes including rates of bleeding, stroke, and target vessel revascularization at 1 year.Overall, 3,858 patients were included in the study (ticagrelor: n = 2,771; prasugrel: n = 1,087), and a majority (48.4%) underwent PCI in the context of CCS. Patients prescribed ticagrelor were more likely to be female, have a history of cerebrovascular disease, and have ACS presentation, while those receiving prasugrel were more likely to be White with a higher prevalence of prior revascularization. No difference in the risk of death or MI was noted across the groups (ticagrelor vs prasugrel: 3.3% vs 3.1%; HR: 0.88; 95% CI: 0.54-1.43; P = 0.59). Rates of target vessel revascularization were significantly lower in the ticagrelor cohort (9.3% vs 14.0%; adjusted HR: 0.71; 95% CI: 0.55-0.91; P = 0.007) with no differences in stroke or bleeding. The results were consistent in patients with CCS (HR: 0.84; 95% CI: 0.46-1.54) and ACS (HR: 1.18; 95% CI: 0.46-1.54), without evidence of interaction (P = 0.37), and confirmed across multivariable adjustment and propensity score stratification analysis.In this contemporary patient population undergoing PCI, prasugrel and ticagrelor were associated with similar 1-year efficacy and safety." @default.
• W4309494706 created "2022-11-28" @default.
• W4309494706 creator A5001555728 @default.
• W4309494706 creator A5004590544 @default.
• W4309494706 creator A5008714150 @default.
• W4309494706 creator A5009530321 @default.
• W4309494706 creator A5012921783 @default.
• W4309494706 creator A5016139987 @default.
• W4309494706 creator A5027745740 @default.
• W4309494706 creator A5034112105 @default.
• W4309494706 creator A5040281800 @default.
• W4309494706 creator A5041952209 @default.
• W4309494706 creator A5044622093 @default.
• W4309494706 creator A5050238434 @default.
• W4309494706 creator A5051193908 @default.
• W4309494706 creator A5059422742 @default.
• W4309494706 creator A5071769101 @default.
• W4309494706 creator A5074896443 @default.
• W4309494706 creator A5079324557 @default.
• W4309494706 creator A5082773155 @default.
• W4309494706 date "2022-11-01" @default.
• W4309494706 modified "2023-09-29" @default.
• W4309494706 title "Ticagrelor vs Prasugrel in a Contemporary Real-World Cohort Undergoing Percutaneous Coronary Intervention" @default.
• W4309494706 cites W1923386888 @default.
• W4309494706 cites W2037191116 @default.
• W4309494706 cites W2056489784 @default.
• W4309494706 cites W2085817407 @default.
• W4309494706 cites W2131184211 @default.
• W4309494706 cites W2138058610 @default.
• W4309494706 cites W2140501627 @default.
• W4309494706 cites W2161055506 @default.
• W4309494706 cites W2169387542 @default.
• W4309494706 cites W2177311071 @default.
• W4309494706 cites W2331820709 @default.
• W4309494706 cites W2752033985 @default.
• W4309494706 cites W2790781247 @default.
• W4309494706 cites W2799954281 @default.
• W4309494706 cites W2808359328 @default.
• W4309494706 cites W2908425650 @default.
• W4309494706 cites W2971019453 @default.
• W4309494706 cites W2971165578 @default.
• W4309494706 cites W2975601412 @default.
• W4309494706 cites W3003672046 @default.
• W4309494706 cites W3031115393 @default.
• W4309494706 cites W3104465182 @default.
• W4309494706 cites W3109408549 @default.
• W4309494706 cites W3139395968 @default.
• W4309494706 cites W3162195278 @default.
• W4309494706 cites W3167233001 @default.
• W4309494706 cites W4200250532 @default.
• W4309494706 cites W4220845915 @default.
• W4309494706 cites W4239728164 @default.
• W4309494706 cites W4292856638 @default.
• W4309494706 doi "https://doi.org/10.1016/j.jcin.2022.09.021" @default.
• W4309494706 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36423970" @default.
• W4309494706 hasPublicationYear "2022" @default.
• W4309494706 type Work @default.
• W4309494706 citedByCount "3" @default.
• W4309494706 countsByYear W43094947062022 @default.
• W4309494706 countsByYear W43094947062023 @default.
• W4309494706 crossrefType "journal-article" @default.
• W4309494706 hasAuthorship W4309494706A5001555728 @default.
• W4309494706 hasAuthorship W4309494706A5004590544 @default.
• W4309494706 hasAuthorship W4309494706A5008714150 @default.
• W4309494706 hasAuthorship W4309494706A5009530321 @default.
• W4309494706 hasAuthorship W4309494706A5012921783 @default.
• W4309494706 hasAuthorship W4309494706A5016139987 @default.
• W4309494706 hasAuthorship W4309494706A5027745740 @default.
• W4309494706 hasAuthorship W4309494706A5034112105 @default.
• W4309494706 hasAuthorship W4309494706A5040281800 @default.
• W4309494706 hasAuthorship W4309494706A5041952209 @default.
• W4309494706 hasAuthorship W4309494706A5044622093 @default.
• W4309494706 hasAuthorship W4309494706A5050238434 @default.
• W4309494706 hasAuthorship W4309494706A5051193908 @default.
• W4309494706 hasAuthorship W4309494706A5059422742 @default.
• W4309494706 hasAuthorship W4309494706A5071769101 @default.
• W4309494706 hasAuthorship W4309494706A5074896443 @default.
• W4309494706 hasAuthorship W4309494706A5079324557 @default.
• W4309494706 hasAuthorship W4309494706A5082773155 @default.
• W4309494706 hasConcept C126322002 @default.
• W4309494706 hasConcept C127413603 @default.
• W4309494706 hasConcept C151730666 @default.
• W4309494706 hasConcept C164705383 @default.
• W4309494706 hasConcept C2777028646 @default.
• W4309494706 hasConcept C2777698277 @default.
• W4309494706 hasConcept C2777849778 @default.
• W4309494706 hasConcept C2779343474 @default.
• W4309494706 hasConcept C2779464278 @default.
• W4309494706 hasConcept C2780400711 @default.
• W4309494706 hasConcept C2780645631 @default.
• W4309494706 hasConcept C2780890252 @default.
• W4309494706 hasConcept C45393284 @default.
• W4309494706 hasConcept C500558357 @default.
• W4309494706 hasConcept C71924100 @default.
• W4309494706 hasConcept C78519656 @default.
• W4309494706 hasConcept C86803240 @default.
• W4309494706 hasConceptScore W4309494706C126322002 @default.
• W4309494706 hasConceptScore W4309494706C127413603 @default.

• next